Evidence map›Paper›PMID 29492227›Full record

ArticleOncotarget2018

The association between BRCA1 gene polymorphism and cancer risk: a meta-analysis.

Gui-Ping Xu, Qing Zhao, Ding Wang, Wen-Yue Xie, Li-Jun Zhang, Hua Zhou, Shi-Zhi Chen, Li-Fang Wu

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Molecular medicine reports · 2023
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Gui-Ping XuTransfusion Department, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Qing ZhaoDepartment of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Ding WangDepartment of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Wen-Yue XieDepartment of Oncology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Li-Jun ZhangDepartment of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Hua ZhouDepartment of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Shi-Zhi ChenDepartment of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Li-Fang WuDepartment of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chongqing Medical University · CNDalian Medical University · CNSecond Affiliated Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many studies have reported that BRCA1 polymorphisms are associated with cancer risk, but the results remain controversial. The purpose of this meta-analysis is to evaluate the relationship between BRCA1 polymorphisms (rs799917, rs1799950, rs1799966, or rs16941) and cancer risk. Relevant studies were identified via a systematic search of the PubMed, Embase, and Web of Science databases up to July 31, 2017. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to examine the strength of the associations. Thirty-five studies published in 19 publications involving 28,094 cases and 50,657 controls were included in this meta-analysis. There was no obvious association between rs799917, rs1799966, or rs16941 polymorphisms and overall cancer risk in any genetic models. However, subgroup analyses revealed that the rs799917 polymorphism could decrease the risk of cervical cancer, esophageal squamous cell carcinoma (ESCC), gastric cancer, and non-Hodgkin lymphoma (NHL) among Asian populations in one or more genetic models and that rs16941 could increase overall cancer risk among Caucasian populations in the homozygote and recessive models. Our meta-analysis also indicated that rs1799950 could decrease the breast cancer (BC) risk among Caucasian populations in the homozygote and recessive models. In summary, our results suggest that BRCA1 polymorphisms may play an important role in the etiology of cancer. However, due to the limited number of studies, these findings should be confirmed by new studies with larger sample sizes that address various types of cancer.

Indexed as

BRCA1cancermeta-analysispolymorphism

Identifiers

PMID29492227
PMCPMC5823592
OpenAlexW2782565095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.